Logo
Contact Us
Dismiss

Human Organoid-based ADC Evaluation Services

Patient-derived human organoid solution for comprehensive ADC efficacy and safety evaluation

Move beyond conventional 2D cell lines and animal models.

Using patient-derived human organoids, we provide clinically relevant evaluation of ADC efficacy, tumor selectivity, mechanism of action, and safety to support confident preclinical decision-making.
Request a Quote

Why Human Organoids Are Essential for ADC Development

Conventional preclinical models are not enough for accurate ADC evaluation.

Conventional 2D Cell Models

  • Unable to reproduce the three-dimensional architecture of human tissues
  • Lack of immune components and the tumor microenvironment (TME)
  • Target expression patterns differ from those observed in human tissues
  • Limited ability to model ADC penetration, internalization, and payload release
Abstract teal circular arcs forming a partial ring on a black background.

Conventional 2D Cell Models

  • Human-relevant Target ExpressionEvaluate ADCs using organoids that preserve clinically relevant target expression patterns.
  • Captures Patient HeterogeneityReflects patient-specific biological characteristics to improve prediction of therapeutic response.
  • Tumor vs. Normal Organoid ComparisonAssess efficacy and safety simultaneously using matched tumor and normal organoid models.
  • Integrated Efficacy and Toxicity AssessmentAnalyze antitumor activity and toxicity within a unified experimental platform.
  • Expression-guided Efficacy EvaluationCompare ADC responses across organoids with different target expression levels.
  • Improved Clinical PredictabilityGenerate human-relevant preclinical data with stronger translational potential for clinical development.

Animal Models

  • Species-specific differences in target expression and drug metabolism
  • Limited cross-reactivity of human-specific antibodies
  • Poor prediction of human organ-specific toxicity

Why Choose logo?

Our ADC evaluation platform is powered by over 3,500 patient-derived organoid lines and advanced TME co-culture models, providing human-relevant data for more predictive preclinical evaluation.

Patient-derived Organoid Lines
0 +
Cancer Types
0 +
Driver Gene Variants
0 +
Immune Co-culture Models
0 +

Patient-derived Human Organoid Solution for ADC Evaluation

Comprehensive evaluation of target expression, efficacy, safety, and tumor selectivity to accelerate next-generation ADC development.

Patient-derived tumor organoids covering major ADC target indications

Visualize and quantify target expression and ADC distribution using Spatial Biology

Organ-specific safety assessment using normal human organoids

TME co-culture models to evaluate ADC penetration, immune interactions, and antitumor activity

Comprehensive Organoid Models for ADC Evaluation

Cancer Organoids

  • Head & Neck Cancer
  • Non-Small Cell Lung Cancer
  • Breast Cancer
  • Hepatocellular Carcinoma
  • Cholangiocarcinoma
  • Pancreatic Cancer
  • Gastric Cancer
  • Colorectal Cancer
  • Renal Cell Carcinoma
  • Endometrial Cancer
  • Ovarian Cancer
  • Prostate Cancer

Normal Organoids

  • Cerebral
  • Midbrain
  • Skin & Hair
  • Retina
  • Lacrimal Gland
  • Salivary Gland
  • Adenoid
  • Tonsil
  • Lung
  • Cardiac
  • Liver
  • Kidney
  • Intestine

Tumor Microenvironment (TME)

  • CAF Co-culture
  • T Cell Co-culture
  • Macrophage Co-culture
  • TME: Macrophages + Cytotoxic T cells
  • TME: CAF + Cytotoxic T Cells
  • TME: CAF + MDSC*
  • TME: Cytotoxic T cells + MDSC*
  • *In development

Additional Analysis Services

  • Multiplex-IHC
  • Holotomography analysis
  • IHC/IF analysis
  • H&E analysis
  • qPCR analysis
  • FACS analysis
  • WES (Whole exome sequencing) analysis
  • ELISA/Multiplex assay
  • scRNA-sequence
  • Bulk-RNA sequence
  • MEA analysis
  • Western blot

Comprehensive ADC Evaluation Workflow

From target expression profiling to efficacy, mechanism of action (MOA), and normal tissue safety evaluation, evaluate ADC candidates through a single integrated human organoid platform.

Model Selection & Stratification

Model Selection & Stratification

✓ Tumor organoid selection

✓ Normal organoid selection

  • Stratify organoid models based on target expression levels (High / Medium / Low)
  • Pre-validation of expression profiles using FACS analysis

Tumor Organoid Efficacy Evaluation

✓ Target Engagement & Internalization

  • ADC internalization
  • ADC binding capacity

✓ Functional Efficacy Assessment

  • IC50 analysis
  • Relative viability

✓ Mechanism of Action (MOA) Analysis

  • Payload-mediated cell death
  • Imaging-based intracellular trafficking

Mechanism of Action (MOA) Analysis

✓ ADC Target Binding Analysis

  • Target Engagement
  • Binding Capacity

✓ Intracellular Transport Analysis

  • Internalization
  • Payload Release

✓ Cell Death Mechanism Analysis

  • Payload-mediated Cytotoxicity
  • Intracellular Trafficking

Normal Organoid Safety Evaluation

✓ Normal Tissue Safety Assessment

  • Intestine, liver, lung, and other normal organoids

✓ Tissue-specific Toxicity Assessment

  • Toxicity analysis using normal human organoids
  • Comparative safety assessment between tumor and normal tissues

Bystander Effect Evaluation

✓ Assessment of Neighboring Cell Response

  • Payload diffusion analysis
  • Bystander cell killing effect

✓ Tumor Microenvironment (TME) Modeling

  • CAF
  • Immune cells
  • Co-culture models

ADC Resistance Model Development

✓ Development of ADC-resistant Models

  • Establishment of resistance models through repeated treatment
  • Platform for evaluating next-generation ADCs

✓ Combination Therapy Evaluation

  • Combination treatment assessment
  • Comparative evaluation of next-generation ADC candidates

Representative Results

ADC efficacy evaluation results

Actionable Insights

Provides key insights to more accurately predict the efficacy and safety of ADC candidate substances.

Tumor Selectivity

Expression-driven Tumor Selectivity

Mechanism of Action

On-target toxicity in normal tissues Organ-specific toxicity signatures Safety margin assessment

Normal Tissue Safety

Tumor efficacy maintained / Normal toxicity minimized Comparative evaluation across ADCs Response prediction (large datasets)

Therapeutic Window Definition

On-target toxicity in normal tissues Organ-specific toxicity signatures Safety margin assessment

Accelerate Your ADC Development with Human Organoids

Submit your request today to receive a customized quote for ORGANOIDSCIENCES’ advanced organoid solutions.
Get a Quote

ORGANOIDSCIENCES

If you have any inquiries about ORGANOIDSCIENCES’ solutions, research collaborations, or partnership opportunities, please leave us a message.
Our team will review your inquiry and connect you with the appropriate expert.
Contact Us